city New Delhi India Britain South Africa covid-19 vaccine strain city New Delhi India Britain South Africa

Novavax' covid-19 vaccine shows 89% efficacy in phase 3 trial

Reading now: 720
www.livemint.com

NEW DELHI : In another potential boost to availability of robust covid-19 vaccines in India, Novavax early Friday announced its interim phase-3 results showing that its protein subunit jabs have an efficacy of 89.3% against the novel coronavirus.More importantly, the efficacy results of the vaccine come from a trial in UK and South Africa, where two more transmissible strains are more prevalent, indicating that the vaccine provides protection against them.Also Read | Covid vaccination faces slow start“NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants," Novavax president and chief executive.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA